PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
11.35%
Net income growth 10-15% – Solid. Seth Klarman would see it as healthy if margins also remain stable.
1.31%
D&A up to 5% yoy – Manageable. Seth Klarman would see normal expansions if revenue justifies the extra depreciation.
No Data
No Data available this quarter, please select a different quarter.
-12.55%
Negative yoy SBC growth reduces new equity issuance. Benjamin Graham would verify that enough talent investment remains for growth.
-199.74%
A negative yoy change in working capital can free up cash. Benjamin Graham would confirm it is not from falling demand or asset disposal.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
AP above 30% yoy – High. Philip Fisher would suspect possible cash strain or very aggressive use of supplier credit.
-382.74%
A negative yoy shift in other WC might free up cash flow. Benjamin Graham would confirm the items are not essential to operations or revenue generation.
-25.35%
A negative yoy shift in other non-cash items can lower reported volatility. Benjamin Graham would confirm it is not concealing real operational costs or artificially inflating net income.
2.31%
Operating cash flow growth 0-5% – Slight. Howard Marks would worry about limited operational momentum unless margins improve.
83.69%
CapEx above 15% yoy – Significant. Philip Fisher would demand strong evidence of high-ROI projects to offset the spending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
83.69%
Above 15% yoy – Heavy. Philip Fisher would require evidence these invests drive future returns and do not hamper free cash flow too much.
No Data
No Data available this quarter, please select a different quarter.
3875.79%
Issuance above 15% yoy – Significant equity raise. Philip Fisher would require a very compelling reason to risk heavy shareholder dilution.
No Data
No Data available this quarter, please select a different quarter.